Actively Recruiting
DPA-714 and FDG PET/MRI in Depression
Led by The First Affiliated Hospital of Dalian Medical University · Updated on 2024-11-12
70
Participants Needed
1
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.
CONDITIONS
Official Title
DPA-714 and FDG PET/MRI in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- No alcohol or psychoactive substances such as coffee consumed in the 24 hours before examination
- Mini-mental State Examination score of 24 points or higher
- Montreal Cognitive Assessment score of 26 points or higher
- No anti-infective drugs used in the past month and no cold, fever, or infection history in the past 2 weeks
- Diabetes patients must have fasting blood sugar below 9.0 mmol/L before examination
- Willing to participate and sign informed consent
- For recurrent depression patients: meet DSM-V criteria for recurrent major depressive disorder
- Age between 35 and 85 years, any gender
- Hamilton Depression Scale score of 8 points or higher
- For first episode depression patients: matched by gender, age, and education level to recurrent group
- Meet DSM-V criteria for first episode depressive disorder
- Hamilton Depression Scale score of 8 points or higher
- For healthy controls: undergoing "DPA-714 or FDG imaging PET/MRI" physical examination at the hospital
- Gender and education level matched to both depression groups
- Never used psychotropic drugs
- Hamilton Depression Scale score below 8 points and Hamilton Anxiety Scale score below 7 points
You will not qualify if you...
- History of organic mental disorders or other mental disorders
- Family history of hereditary diseases
- Mental retardation or dementia
- History of psychoactive substance abuse
- Unable to cooperate with or complete psychological examination scales
- Serious physical diseases affecting heart, brain, liver, lung, or kidney
- MRI contraindications or abnormalities found in head CT or MRI
- History of drug or alcohol abuse
- History of metabolic diseases such as hyperthyroidism, hypothyroidism, or rheumatic diseases
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China, 116000
Actively Recruiting
Research Team
H
Huimin Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here